Nervous System News and Research

Latest Nervous System News and Research

Renowned experts discuss new approaches to cancer therapy at international conference

An international conference attended by more than 70 of the world's leading experts and investigators in the field of Ephs and ephrins was held locally this week and hosted by Waldemar Debinski, M.D., Ph.D., director of the Brain Tumor Center of Excellence at Wake Forest University Baptist Medical Center.

30 Jun 2010

Vimpat provides long-term additional partial-onset seizure control when added to broad range of AEDs

New long term data showed that Vimpat- (lacosamide) C-V provided sustained reduction in seizure frequency for up to five years when used as an add-on treatment for uncontrolled partial onset seizures in adults with epilepsy. In addition post-hoc exploratory analyses showed that adjunctive lacosamide treatment reduced partial-onset seizure frequency and improved responder rates when added to a broad range of antiepileptic drugs (AEDs) including both traditional sodium channel-blocking agents and those that act on non-sodium channel-targets.

30 Jun 2010

UK scientists find no link between mobile phone masts and early childhood cancers

UK scientists have found no evidence to suggest that children whose mothers lived close to mobile phone base stations during pregnancy face an increased risk of early childhood cancers.

30 Jun 2010

UCLA School of Dentistry awarded NIH grant to study methamphetamine's oral, dental health consequences

The abuse of methamphetamine - a powerful and highly addictive psychostimulant that is toxic to the nervous system - has reached epidemic proportions in many parts of the United States. The National Institute on Drug Abuse estimates that more than 10 million Americans have tried methamphetamine, while more than 1.4 million are habitual users.

30 Jun 2010

Alnylam receives Portuguese, Swedish, British approvals to initiate ALN-TTR01 Phase I study in ATTR

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that its applications for ALN-TTR01 have been given clearance by Portuguese, Swedish, and British regulatory authorities to begin clinical testing. The trial will begin enrolling patients shortly in a blinded, randomized, placebo-controlled, multicenter Phase I study.

29 Jun 2010

BBD reports analyze effectiveness and safety of statin use

A series of new reports from Consumer Reports Best Buy Drugs (BBD) caution that the benefits of statin use by children and some women may not outweigh the risks. Drugs to lower cholesterol - including statins - are the most commonly prescribed drugs in the U.S. and garnered more than $14 billion in sales last year.

29 Jun 2010

Chelsea initiates NORTHERA Phase III trial for symptomatic NOH associated with PD

Chelsea Therapeutics International, Ltd. announced the initiation of Study 306, a pivotal Phase III trial evaluating the efficacy of NORTHERA™, an oral synthetic precursor of norepinephrine, for the treatment of symptomatic neurogenic orthostatic hypotension (NOH) associated with Parkinson's disease.

29 Jun 2010

A natural approach to combat stress

For anyone who knows the racing, "misfiring" brain associated with today's multitasking lifestyles, finding a safe, effective remedy to achieve calm can be a challenge. Women-run Rainbow Light® Nutritional Systems, a leader in natural nutrition for nearly 30 years, has developed a breakthrough remedy to calm the "busy brain" that can impair mental clarity and cause restless sleep.

29 Jun 2010

Researchers study mechanism of human brain

Because of its intricate organization, figuring out the wiring diagram that explains how the billions of neurons in the brain are connected, and determining how they work together, remains a formidable task.

29 Jun 2010

Rexahn announces $10 million registered direct offering

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced it has received commitments from certain institutional investors to purchase an aggregate of $10 million of Rexahn's securities in a registered direct offering.

28 Jun 2010

AMP comments on barriers to market for molecular diagnostic tests at FDA CDRH meeting

Yesterday, the Association for Molecular Pathology (AMP) gave public comments at the FDA's Center for Devices and Radiological Health (CDRH) Council meeting on Medical Device Innovation: Barriers to Market for Molecular Diagnostic Tests.

28 Jun 2010

Merck challenges New York jury decision in federal FOSAMAX retrial

Merck & Co., Inc. today said it is challenging the decision returned by a New York jury in the retrial of a federal FOSAMAX case, Boles v. Merck. This case was the Plaintiffs' Steering Committee's top choice to take to trial and involved a Florida woman who blamed her dental and jaw problems on FOSAMAX. The first case to reach a verdict, Maley v. Merck, resulted in a defense verdict for Merck on May 5, 2010.

28 Jun 2010

Orexigen Therapeutics announces data from CORDiabetes trial for Contrave

Orexigen Therapeutics, Inc. today announced data from the CORDiabetes trial for Contrave (naltrexone sustained release (SR)/bupropion SR) showing that after 56 weeks of treatment, overweight or obese patients with type 2 diabetes lost significantly more weight and achieved greater improvement in glycemic control than those treated with placebo.

28 Jun 2010

Arena's lorcaserin reduces body weight across patient subgroups

Arena Pharmaceuticals, Inc. today reported pooled Week 52 data from more than 6,000 patients in lorcaserin's pivotal Phase 3 clinical trial program that demonstrate lorcaserin 10 mg dosed twice daily reduced body weight in all patient subgroups evaluated, as defined by gender, age, ethnicity and starting body weight and Body Mass Index (BMI). Greater improvements in cardiovascular risk factors were also achieved with lorcaserin treatment compared to placebo overall and in most subgroups.

28 Jun 2010

Phase 2b clinical trial data of SGLT2 inhibitor in patients with type 2 diabetes presented at ADA 2010

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that canagliflozin, an investigational, oral, selective sodium-glucose transporter-2 inhibitor, improved glycemic control, and was also associated with a decrease in body weight, in a Phase 2b dose-ranging trial in patients diagnosed with type 2 diabetes who were concurrently treated with metformin. The data were presented at the 70th American Diabetes Association Scientific Sessions.

28 Jun 2010

Additional results from BLISS-76 Phase 3 trial of BENLYSTA presented at International Congress on SLE

Human Genome Sciences, Inc. today announced the presentation of additional results from BLISS-76, one of two pivotal Phase 3 trials of BENLYSTA (belimumab) in seropositive patients with systemic lupus erythematosus. The additional data will be presented in Vancouver at the 9th International Congress on Systemic Lupus Erythematosus on Friday and Saturday, June 25-26.

28 Jun 2010

Athersys, CSCRM and CWRU receive $1M to advance MultiStem therapy for SCI

Athersys, Inc. and its collaborators, including the Center for Stem Cell and Regenerative Medicine and Case Western Reserve University, announced today that they have been awarded $1 million through the Ohio Third Frontier Biomedical Program to support research into the treatment of spinal cord injury with MultiStem, Athersys' proprietary stem cell product candidate.

25 Jun 2010

Neuralstem signs definitive agreements to sell $10M of units in registered-direct offering

Neuralstem, Inc. announced today that it has entered into definitive agreements to sell $10 million of units at $2.80 per unit in a registered-direct offering to institutional investors. The units consist of: (i) one share of common stock, and (ii) 3/4 common stock purchase warrant. The warrants have an exercise price of $3.25 and a term of three years.

25 Jun 2010

Scientists discover characteristic amyloid plaques in retinas from Alzheimer's disease patients

The nerve cell-damaging plaque that builds up in the brain with Alzheimer's disease also builds up in the retinas of the eyes - and it shows up there earlier, leading to the prospect that noninvasive optical imaging of the eyes could lead to earlier diagnosis, intervention and monitoring of the disease, according to new research.

25 Jun 2010

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

Merck announced that the Committee for Medicinal Products for Human Use adopted a positive opinion on the pending Marketing Authorization Application for SYCREST (asenapine) sublingual tablets. The CHMP has recommended that the European Commission grant a marketing authorization for SYCREST for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. The CHMP did not support an indication for the treatment of schizophrenia.

25 Jun 2010

Nervous System News and Research

Latest Nervous System News and Research

Renowned experts discuss new approaches to cancer therapy at international conference

Vimpat provides long-term additional partial-onset seizure control when added to broad range of AEDs

UK scientists find no link between mobile phone masts and early childhood cancers

UCLA School of Dentistry awarded NIH grant to study methamphetamine's oral, dental health consequences

Alnylam receives Portuguese, Swedish, British approvals to initiate ALN-TTR01 Phase I study in ATTR

BBD reports analyze effectiveness and safety of statin use

Chelsea initiates NORTHERA Phase III trial for symptomatic NOH associated with PD

A natural approach to combat stress

Researchers study mechanism of human brain

Rexahn announces $10 million registered direct offering

AMP comments on barriers to market for molecular diagnostic tests at FDA CDRH meeting

Merck challenges New York jury decision in federal FOSAMAX retrial

Orexigen Therapeutics announces data from CORDiabetes trial for Contrave

Arena's lorcaserin reduces body weight across patient subgroups

Phase 2b clinical trial data of SGLT2 inhibitor in patients with type 2 diabetes presented at ADA 2010

Additional results from BLISS-76 Phase 3 trial of BENLYSTA presented at International Congress on SLE

Athersys, CSCRM and CWRU receive $1M to advance MultiStem therapy for SCI

Neuralstem signs definitive agreements to sell $10M of units in registered-direct offering

Scientists discover characteristic amyloid plaques in retinas from Alzheimer's disease patients

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Nervous System News and Research

Latest Nervous System News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in